Indivior
INDV
Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them
Managers holding
1
In their latest 13F (Q3 2026)
See who
Value held
$251m
Combined value at quarter end
Last quarter
0 bought
1 sold or trimmed
Price at Q4 ’25 end
$35.88
Share price change by quarter
-26.8%Q2 ’24
-37.0%Q3 ’24
+29.8%Q4 ’24
-26.7%Q1 ’25
+56.9%Q2 ’25
Managers holding it, by quarter
0Q4 ’23
1Q1 ’24
1Q2 ’24
1Q3 ’24
1Q4 ’24
1Q1 ’25
1Q2 ’25
1Q3 ’25
1Q4 ’25
1Q1 ’26
1Q2 ’26
0Q3 ’26
Who holds it
| Oaktree Capital Management | 3.5%$251m | Trimmed -12% |
Directors buying and selling
How this works
| Bought or sold | ||||
|---|---|---|---|---|
| 27 Aug 2026 | Anderson Woodrow DChief Accounting Officer | ▲ Bought | 1,500 | $54k |
| 5 Aug 2026 | Anderson Woodrow DChief Accounting Officer | ▲ Bought | 1,500 | $54k |
About the company
- Sector
- Health care · Pharmaceutical Preparations
- Incorporated in
- Delaware
- Financial year ends
- 31 December
- Shares outstanding
- 118m at 28 Jul 2026
- SEC filings
- Annual reports and other filings on EDGAR
Revenue and profit
$901m2022
$1.1bn2023
$1.2bn2024
$1.2bn2025
| Year | Revenue | Net income |
|---|---|---|
| 2025 | $1.2bn | $210m |
| 2024 | $1.2bn | $7.0m |
| 2023 | $1.1bn | −$126m |
| 2022 | $901m | −$42.0m |